Untitled source document
No live link available for this source.
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Payload differentiation will become increasingly important as more cancer patients receive ADCs as front-line therapy and develop resistance to current ADC payload classes, leaving limited subsequent therapy options.
60% confidenceADC-refractory patients are a significant, growing unmet need and an exclusive opportunity for Akari's novel payload, which current and most future ADCs will not be able to access.
60% confidenceEmerging clinical data presented at major medical conferences show that sequential ADC treatment using the same payload class does not provide benefit after relapse.
60% confidenceGauging interest in the novel payload technology at conferences left him more convicted in Akari's technology, strategy and execution; PH1 generated meaningful interest and reinforced the belief that differentiated payloads will play an increasingly important role as ADC therapies evolve.
60% confidenceAKTX-101 is planned to advance to Phase 1 clinical development in mid-2027.
60% confidence